2561.HK

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Drug Manufacturers - Specialty & Generic

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$71M	+1322.5%	$-2.23	$-2.23–$-2.23	—	1
2027	$336M	+372.2%	$-2.41	$-2.41–$-2.41	—	1
2028	$903M	+169.1%	$-1.35	$-1.35–$-1.35	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$7.68

Price

$19.27

Implied downside

-60%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
2561.HKVISEN Pharmaceuticals	$19.28	+0.26%	$2.1B	—
1515.HKChina Resources Medical Holdings Company Limited	$2.38	-0.83%	$3.0B	—
2410.HKTYK Medicines, Inc	$3.52	-5.76%	$1.3B	—
2509.HKQyuns Therapeutics Co., Ltd.	$16.45	-0.96%	$3.7B	—
2552.HKHua Medicine (Shanghai) Ltd.

VISEN Pharmaceuticals

VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.

www.visenpharma.com/cn

Employees: 82
IPO / List date: Mar 21, 2025
HQ: CN

Held by traders on TradeandTell

No one on the platform currently holds 2561.HK.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 2561.HK as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 2561.HK yet.